Galantamine


BACK

ORDER


References www.AlzheimersTreatments.com

  1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease [letter]. Lancet 1976 Dec 25;2(8000):1403.
  2. Fryxell KJ. The evolutionary divergence of neurotransmitter receptors and second-messenger pathways. J Mol Evol 1995 Jul;41(1):85-97.
  3. Winblad B, Hardy J, Backman L, Nilsson LG. Memory function and brain biochemistry in normal aging and in senile dementia. Ann NY Acad Sci 1985;444:255-68.
  4. Mantle D, Pickering AT, Perry EK. Medicinal plant extracts for the treatment of dementia: a review of their pharmacology, efficacy and tolerability. CNS Drugs 2000;13(3):201-13.
  5. Schneider LS. The future of cholinergic replacement therapy in Alzheimer’s disease. Curr Opin CPNS Invest Drugs 2000;2(4):427-37.
  6. Shah S, Tangalos EG, Petersen RC. Mild cognitive impairment. When is it a precursor to Alzheimer’s disease? Geriatrics 2000 Sep;55(9):62,65-8. Review.
  7. Davis KL, Mohs RC, Marin DB, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry 1999 Nov;56(11):981-7.
  8. Ludianskii EA. On the use of anticholinesterase agents in the treatment of neurological diseases. Sov Med 1964 Mar;27:84-7.
  9. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer’s disease. Behav Brain Res 2000 Aug;113(1-2):199-206.
  10. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000 Jun 27;54(12):2261-8.
  11. Gaykema RP, Gaal G, Traber J, Hersh LB, Luiten PG. The basal forebrain cholinergic system: efferent and afferent connectivity and long-term effects of lesions. Acta Psychiatr Scand Suppl 1991;366:14-26.
  12. Iraizoz I, Guijarro JL, Gonzalo LM, de Lacalle S. Neuropathological changes in the nucleus basalis correlate with clinical measures of dementia. Acta Neuropathol (Berl) 1999 Aug;98(2):186-96.
  13. Maneesub Y, Sanvarinda Y, Govitrapong P. Partial restoration of choline acetyltransferase activities in aging and AF64A-lesioned rat brains by vitamin E. Neurochem Int 1993 May;22(5):487-91.
  14. Geula C, Mesulam MM, Saroff DM, Wu CK. Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease. J Neuropathol Exp Neurol 1998 Jan;57(1):63-75.
  15. Maelicke A. Allosteric Modulation of nicotinic receptors as a treatment strategy for Alzheimer’s disease. Dement Geriatr Cogn Disord 2000 Sep;11 Suppl 1:11-8.
  16. Galantamine improves memory and learning ability in Alzheimer’s patients. July 20, 1998. http://www.pslgroup.com/dg/8F5D6.htm.

BACK

ORDER